Ignite Creation Date:
2025-12-26 @ 11:14 AM
Ignite Modification Date:
2025-12-29 @ 5:54 PM
Study NCT ID:
NCT03302728
Status:
COMPLETED
Last Update Posted:
2022-05-19
First Post:
2017-10-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma
Sponsor:
Peter MacCallum Cancer Centre, Australia
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-08-30
Start Date Type:
ACTUAL
Primary Completion Date:
2021-08-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-08-02
Completion Date Type:
ACTUAL
First Submit Date:
2017-10-01
First Submit QC Date:
None
Study First Post Date:
2017-10-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-05-17
Last Update Post Date:
2022-05-19
Last Update Post Date Type:
ACTUAL